Deal Intelligence Platform & Services for Global M&A / PE
2021 brought a flurry of #MnA activity in the life sciences sector, followed by a slowdown in 2022. Here’s why dealmaking could pick up again. deloi.tt/3PIOHZP
– Deloitte M&A (@DeloitteMnA)09:00 – Aug 31, 2022
TL;DR Brussels-based biopharma UCB will acquire Candid Therapeutics for up to $2.2 billion, comprised of a $2.0 billion upfront cash payment and $200 million in milestones. The deal centers on...
TL;DR Mumbai-based Sun Pharmaceutical Industries Ltd. is finalizing a binding $12 billion offer for Organon & Co., marking the largest overseas acquisition in Indian pharma history. The deal is...
TL;DR Merck & Co. has launched a $6.7 billion all-cash unsolicited offer for Terns Pharma, a biotech firm specializing in small-molecule drug candidates for metabolic disorders like NASH. The...
TL;DR Alcon terminated its agreement to acquire Lensar for up to $430 million on March 17, 2026, citing a protracted, year-long regulatory review by the Federal Trade Commission (FTC). The FTC...